Nakamura Sou

Research field (1)： Biomedical engineering

Research theme for competitive and other funds (5)：

2021 - 2026 Elucidating the fundamental mechanism of platelet biogenesis and its medical application
2022 - 2025 巨核球成熟における一次絨毛由来小胞の生理機能解明および生体外血小板製造への応用
2021 - 2022 流体刺激シグナルの解明に基づく連続血小板製造非定常培養機器の開発
2018 - 2022 New method for establishing self-renewing megakaryocyte cell lines using iPS cells
2018 - 2021 Mechanism of turbulence mediated platelet biogenesis and application to ex vivo manufacturing of platelets

Papers (35)：

Haruki Okamoto, Kosuke Fujio, Sou Nakamura, Yasuo Harada, Hideki Hayashi, Natsumi Higashi, Atsushi Ninomiya, Ryota Tanaka, Naoshi Sugimoto, Naoya Takayama, et al. Defective flow space limits the scaling up of turbulence bioreactors for platelet generation. Communications Engineering. 2024
Si Jing Chen, Kazuya Hashimoto, Kosuke Fujio, Karin Hayashi, Sudip Kumar Paul, Akinori Yuzuriha, Wei-Yin Qiu, Emiri Nakamura, Maria Alejandra Kanashiro, Mio Kabata, et al. A let-7 microRNA-RALB axis links the immune properties of iPSC-derived megakaryocytes with platelet producibility. Nature Communications. 2024. 15. 1
Maria Alejandra Kanashiro, Sudip Kumar Paul, Masamitsu Sone, Ikuyo Yoshino, Kyoko Tsujimura, Makoto Ikeya, Sou Nakamura, Koji Eto, Naoya Takayama. iPSC-Derived Mesenchymal Stem Cells Supports the Ex Vivo expansion of Human Hematopoietic Stem and Progenitor Cells Via Sterile Inflammation Pathway. Blood. 2023. 142. Supplement 1. 2680-2680
Charlotte Flahou, Tatsuya Morishima, Natsumi Higashi, Yoshikazu Hayashi, Huaigeng Xu, Bo Wang, Chaoqi Zhang, Atsushi Ninomiya, Wei-Yin Qiu, Akinori Yuzuriha, et al. Humanized mouse models with endogenously developed human natural killer cells for in vivo immunogenicity testing of HLA class I-edited iPSC-derived cells. Biochemical and biophysical research communications. 2023. 662. 76-83
林智也, 三島優一, 中村壮, 杉本直志, 堀田秋津, 正木美香子, 田中光信, 石井博之, 立山英美, 藤村吉博, et al. ゲノム編集技術を用いたiPS細胞由来特異的HPA発現パネル細胞株の開発 HPA-3a抗体の特異的な検出. 日本輸血細胞治療学会誌. 2023. 69. 2. 283-283

ｍore...

MISC (34)：

中村壮, 江藤浩之. 【ヒトの再生をめぐる諸問題】iPS細胞由来血小板製剤の開発. HORMONE FRONTIER IN GYNECOLOGY. 2023. 30. 1. 37-42
中村壮, 江藤浩之. iPS細胞由来血小板製剤の開発. 検査と技術. 2023. 51. 1. 44-47
杉本直志, 中村壮, 江藤浩之. 【血液疾患と血球分化】血小板産生における流体力学機序乱流による血小板大量産生. 血液内科. 2021. 82. 1. 23-29
中村壮, 江藤浩之. 新規物理化学制御機構が1,000億個の血小板作製を可能にする. 臨床血液. 2020. 61. 6. 628-633
高石浩司, 武内正博, 塚本祥吉, 高山直也, 大島基彦, 中村壮, 江藤浩之, 岩間厚志, 横手幸太郎, 中世古知昭, et al. iPS細胞由来巨核球系前駆細胞株を用いたアナグレリドによる血小板産生抑制機構の解明. 日本臨床分子医学会学術総会プログラム・抄録集. 2019. 56回. 53-53

ｍore...

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page